| Applications: |
ELISA |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Sensitivity: |
23.4 pg/mL |
| Detection Limit: |
46875-3000 pg/ml |
| Short Description: |
This IL27 Sandwich ELISA Kit is an in-vitro enzyme-linked immunosorbent assay for the measurement of samples in human cell culture supernatant, serum and plasma (EDTA, citrate, heparin). |
| Conjugation: |
Biotin |
| Storage Instruction: |
Unopened kits can be stored at 2-8°C for 1 year, and opened products must be used within 1 month. |
| Assay Time: |
4 hours |
| Detection: |
Colorimetric |
| Gene Symbol: |
IL27 |
| Gene ID: |
246778 |
| Uniprot ID: |
IL27A_HUMAN |
| Sample Type: |
serum, plasma and cell culture supernates |
| Tissue Specificity | Expressed in monocytes and in placenta. |
| Post Translational Modifications | O-glycosylated. |
| Function | Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of pro-inflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses pro-inflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication. |
| Protein Name | Interleukin-27 Subunit AlphaIl-27 Subunit AlphaIl-27-AIl27-AInterleukin-30P28 |
| Database Links | Reactome: R-HSA-9020956 |
| Cellular Localisation | SecretedDoes Not Seem To Be Secreted Without Coexpression Of Ebi3 |
| Alternative ELISA Names | Interleukin-27 Subunit Alpha ELISA kitIl-27 Subunit Alpha ELISA kitIl-27-A ELISA kitIl27-A ELISA kitInterleukin-30 ELISA kitP28 ELISA kitIL27 ELISA kitIL27A ELISA kitIL30 ELISA kit |
| output | |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
